CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications
August 9th, 2022
The present protocol describes an optimized hematopoietic stem and progenitor cell (HSPC) culture procedure for the robust engraftment of gene-edited cells in vivo.
Overview
This study presents an optimized protocol for ex vivo culture of hematopoietic stem and progenitor cells (HSPCs) to enhance the engraftment of gene-edited cells in vivo. The method focuses on preserving the stemness of HSPCs during culture, thereby improving the efficacy of hemopoietic stem cell gene therapy for diseases, including HIV.
Key Study Components
Research Area
- Hematopoietic stem cell biology
- Gene therapy for monogenic and infectious diseases
- Optimization of cell culture protocols
Background
- Challenges in ex vivo culture affecting repopulation potential
- Importance of maintaining stemness in HSPCs for successful gene therapy
- Relevance of HSPC gene therapy in current medical practice
Methods Used
- Cytokine and small molecule supplementation in culture media
- Gene editing with chemically-modified sgRNA
- Nucleofection and intravenous injection in mouse model systems
Main Results
- Improved frequency of CD34-positive, CD90-positive cells
- Increased gene editing efficiency in RUS-treated cells
- Demonstrated compatibility with various ex vivo culture procedures
Conclusions
- The study presents a refined protocol that enhances the engraftment of gene-modified HSPCs.
- This approach is significant for advancing gene therapy techniques and their clinical applicability.
Frequently Asked Questions
Executive Industry Relevance
Optimized CRISPR/Cas9 gene editing in hematopoietic stem and progenitor cells (HSPCs) addresses a critical bottleneck in gene therapy by preserving stemness and enhancing engraftment potential. This protocol enables higher yields of functional, gene-modified HSPCs, directly impacting early-stage target validation and translational continuity for monogenic and infectious disease programs. The approach supports robust pipeline advancement by improving predictive confidence in preclinical models and facilitating risk-adjusted portfolio decisions.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of therapeutic hypotheses in disease-relevant HSPC systems.
- Supports functional target validation by maintaining multilineage repopulation capacity post-editing.
- Improves predictive confidence for gene therapy feasibility in preclinical settings.
Screening & Assay Development
- Establishes standardized, reproducible ex vivo culture conditions for HSPCs.
- Facilitates quantitative assessment of gene-editing efficiency and cell viability.
- Prepares validated, gene-modified HSPCs for downstream in vivo functional assays.
Translational & Preclinical Research
- Aligns in vitro gene-editing outputs with in vivo engraftment and repopulation benchmarks.
- Enables continuity from discovery-stage editing to preclinical validation in mouse models.
- Supports translational biomarker analysis through CD34 and CD90 marker quantification.
Pipeline & Workflow Integration
This protocol integrates from early discovery through preclinical validation, supporting gene-editing hypothesis testing, functional assessment, and in vivo translation.
- Discovery Biology: Preserves HSPC stemness for robust hypothesis testing and pathway de-risking.
- Screening: Delivers reproducible, quantitative gene-editing outputs for assay development.
- Analytics: Provides flow cytometry-based readouts for CD34/CD90 and gene-editing frequency.
- Translational Research: Bridges in vitro editing with in vivo engraftment and functional repopulation.
- Enterprise Reuse: Protocol compatibility with diverse ex vivo HSPC workflows enhances platform value.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in gene therapy programs.
- Operational Value: Standardizes HSPC culture and editing for reproducibility and scalability.
- Strategic Value: Improves go/no-go decision quality and capital efficiency in early-stage gene therapy pipelines.
- Portfolio Impact: Enables risk-adjusted prioritization of gene-editing candidates for advancement.
Implementation Considerations
- Requires expertise in HSPC isolation, culture, and CRISPR/Cas9 gene editing.
- Demands access to nucleofection instrumentation and flow cytometry analytics.
- Necessitates cross-team standardization of culture conditions and analytical endpoints.
- Adaptable to cord blood and iPSC-derived HSPCs as supported by ongoing testing.
- Dependent on maintaining optimal cell density and small molecule supplementation for maximal engraftment.
Biopharma FAQs
Chapters in this video
0:04
Introduction
0:53
Gene Editing of HSPCs
2:55
Transplantation of Gene-Edited HSPCs
4:39
Assessment of Short-Term Engraftment Potential
5:17
Assessment of Long-Term Engraftment Potential
7:01
Results: Evaluating the Efficiency of CRISPR/Cas9 Gene Editing of HSPCs
7:58
Conclusion
